Skip to main content

Advertisement

SpringerLink
Log in

Advanced non-small cell lung cancer

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

The treatment of advanced non-small cell lung cancer requires histologic proof of diagnosis, careful staging, and assessment of each patient’s performance status and comorbidities. For patients with stage IIIB (pleural effusion) and stage IV disease who have a Cancer and Leukemia Group B performance status (PS) of 0 to 1, appropriate management consists of combination chemotherapy with a platinum (either cisplatin or carboplatin) combined with paclitaxel, gemcitabine, vinorelbine, docetaxel, or CPT-11. Dosages and schedules previously established by large phase II or phase III studies should be followed. Variations in the toxicity patterns, schedules of administra-tion, and economic considerations should guide the selection of the specific regimen. For patients who maintain a good performance status after first-line chemotherapy, second-line treatment may be considered. Current evidence supports the use of docetaxel as second-line treatment if the patient has not previously received this drug. Gemcitabine and paclitaxel may also have activity in this setting. Vinorelbine, ifosfamide, and CPT-11 appear to be inactive as second-line therapy for patients who have previously received platinum-based chemotherapy. For patients with a PS of 2, single-agent chemotherapy with vinorelbine, gemcitabine, or a combination of the two should be considered. Patients with poor performance status should be treated with supportive measures designed to relieve pain and acute complications because any tumor-directed therapy has limited benefit. Special situations exist in which curative therapy for metastatic disease is a possibility. Patients who present with solitary sites of metastatic disease, particularly after a long disease-free interval and in the CNS may undergo definitive surgery or radiotherapy with curative intent. Some have also reported favorable outcomes for patients with solitary adrenal or bone metastases as well. Surgical treatment or definitive radiotherapy should not be employed unless a thorough restaging evaluation is performed that includes computed tomography scan of the chest and abdomen through adrenals, brain magnetic resonance imaging, and positron emission tomography scan. A plethora of new agents targeting angiogenesis, tumor invasiveness, the hypoxic environment of tumors, and the cell cycle are currently in development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995, 311:899.

    Google Scholar 

  2. Helsing M, Bergman, Thaning L, Hero U, for the Joint Lung Cancer Study Group: Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicenter randomized phase III trial. Eur J Cancer 1998, 34:1036–1044.

    Article  PubMed  CAS  Google Scholar 

  3. Cullen MH, Billingham LJ, Woodroffe CM, et al.:Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999, 17:3188–3194. This large, randomized, phase III study should forever put to rest any question about the palliative importance of chemotherapy in NSCLC.

    PubMed  CAS  Google Scholar 

  4. Mather D, Sullivan SD, Parasuraman TV: Beyond survival: economic analyses of chemotherapy in advanced, inoperable NSCLC. Oncology 1998, 12:199–209.

    PubMed  CAS  Google Scholar 

  5. Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer. J Clin Oncol 1997, 15:2996–3018.

  6. Johnson DH, Zhu J, Schiller J, et al.: E-1594: a randomized phase III trial in metastatic non-small cell lung cancer (NSCLC). Outcome of PS 2 patients (pts): an Eastern Cooperative Group Trial (ECOG). Proc Am Soc Clin Oncol 1999, 18:461a.

    Google Scholar 

  7. Elderly Lung Cancer Vinorelbine Italian Study Group: Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 1999, 91:66–72. A randomized, phase III study demonstrating that single-agent vinorelbine improved outcome both in terms of survival and quality of life in elderly (over 70 years) patients.

    Article  Google Scholar 

  8. Frasci G, Lorusso V, Panza N, et al.: Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer. J Clin Oncol 2000, 18:2529–2536.

    PubMed  CAS  Google Scholar 

  9. Green MR, Kramar A, Schilsky R, et al.: Platinum based combination chemotherapy in advanced non-small cell lung cancer: a randomized phase II study of the Cancer and Leukemia Group B. Med Pediatr Oncol 1990, 18:197–202.

    Article  PubMed  CAS  Google Scholar 

  10. Gandara DR, Perez EA, Wold HG, et al.: High-dose cisplatin and mitomycin C in advanced non-small cell lung cancer: a phase II study of the Northern California Oncology Group. Cancer Chemother Pharmacol 1990, 27:243–247.

    Article  PubMed  CAS  Google Scholar 

  11. Jaakkimainen L, Goodwin PJ, Pater J, et al.: Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in non-small cell lung cancer. J Clin Oncol 1990, 8:1301–1309.

    PubMed  CAS  Google Scholar 

  12. Kelly K, Crowley J, Bunn PA, et al.: A randomized Phase III study of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in untreated advanced non-small cell lung cancer: a Southwest Oncology Group trial. Proc Am Soc Clin Oncol 1999, 18:461a. The first randomized phase III study comparing two new regimens in NSCLC. The results, a dead heat, demonstrate that there is no clearly superior regimen.

    Google Scholar 

  13. Schiller JH, Harrington D, Sandler A, et al.: A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 2000, 19:1.

    Google Scholar 

  14. Kosmidis PA, Mylonakis N, Skarlos D, et al.:A multicenter randomized trial of paclitaxel (175 mg/m 2 ) plus carboplatin (6AUC) versus paclitaxel (225 mg/m 2 ) plus carboplatin (6AUC) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1999, 18:463a.

    Google Scholar 

  15. Ramsey SD, Moinpour CM, Lovato LC, et al.:An economic analysis of Southwest Oncology Group Trial S9509: cisplatin/vinorelbine vs. carboplatin/ paclitaxel for advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2000, 19:489a.

    Google Scholar 

  16. Bonomi PD, Finkelstein DM, Ruckdeschel JC, et al.:Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989, 7:1602–1613.

    PubMed  CAS  Google Scholar 

  17. Klastersky J, Sculier JP, Laccroiz H, et al.: A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol 1990, 8:1556–1562.

    PubMed  CAS  Google Scholar 

  18. Gatzemeier U, Rosell R, Belticher D, et al.: Randomized pan-European trial comparing paclitaxel/carboplatin versus paclitaxel/cisplatin in advanced non-small cell lung cancer. Proc ECCO 1999, 10:973.

    Google Scholar 

  19. Lilenbaum R: Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: a meta-analysis of response, toxicity, and survival. Cancer 1998, 82:116–126.

    Article  PubMed  CAS  Google Scholar 

  20. Akerly W, Herndon J, Egorin MJ, et al.: CALGB 9731: a phase II trial of weekly paclitaxel for advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1999, 18:462a.

    Google Scholar 

  21. Pectasides D, Aspropotamitis A, Halikia A, et al.:Combination chemotherapy with carboplatin, docetaxel, and gemcitabine in advanced non-small cell lung cancer: a phase II study. Eur J Cancer 2000, 36:74–79.

    Article  PubMed  CAS  Google Scholar 

  22. Comella P, Frasci G, Panza N, et al.: Interim analysis of a phase III trial of the Southern Italy Cooperative Oncology group. Randomized trial comparing cisplatin, gemcitabine and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer. J Clin Oncol 2000, 18:1451–1457.

    PubMed  CAS  Google Scholar 

  23. Wozniak AJ, Crowley JJ, Balcerzak S, et al.: Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998, 16:2457–2465.

    Google Scholar 

  24. von Pawel J, von Roemling R, Gatzemeir U, et al.:Tirapazamine plus cisplatin versus cisplatin in advanced non-small cell lung cancer: a report of the International CATAPULT I Study Group. J Clin Oncol 2000, 18:2457–2465.

    Google Scholar 

  25. Edelman MJ, Gandara DR, et al.: Sequential carbo-platin/ gemcitabine (C/G) -> paclitaxel (P) in advanced NSCLC: an effective and well tolerated regimen. Proc Am Soc Clin Oncol 1999, 18:520a.

    Google Scholar 

  26. Qamar R, Clark JI, Fisher S, et al.: Phase II study of cisplatin and vinorelbine followed by docetaxel for selected IIIb and stage IV non-small cell lung cancer. Preliminary results. Proc Am Soc Clin Oncol 1999, 18:520a.

    Google Scholar 

  27. Georgoulias V, Papadakis E, Alexopoulos A, et al.: Doce-taxel + cisplatin vs docetaxel + gemcitabine chemo-therapy in advanced non small cell lung cancer: a preliminary analysis of a multicenter randomized phase II trial [abstract]. Proc Am Soc Clin Oncol 1999, 18:461.

    Google Scholar 

  28. Kosmidis PA, Bacoyiannis C, Mylonakis N, et al.:A randomized phase III trial of paclitaxel + carbo-platin vs paclitaxel + gemcitabine in advanced non small cell lung cancer (NSCLC). A preliminary analysis. Hellenic Cooperative Oncology Group (HeCOG). Proc Am Soc Clin Oncol 2000, 19:488a.

    Google Scholar 

  29. Rak JW, St Croiz BD, Kerbel RS: Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs 1995, 6:3–18.

    Article  PubMed  CAS  Google Scholar 

  30. Senderowicz AM, Sausville EA: Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 2000, 92:376–387.

    Article  PubMed  CAS  Google Scholar 

  31. Brown JM, Giaccia AJ: The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998, 58:1408–1416.

    PubMed  CAS  Google Scholar 

  32. Le Chevalier T, Gatineau M, Daniel C, et al.: Phase II study of the combination of vinorelbine, cisplatin and tirapazamine in advanced non-small cell lung cancer (NSCLC). Proc ASCO 1999, 18:491a.

    Google Scholar 

  33. Smith IE, O’Brien MER, Norton A, et al.: Duration of chemotherapy for advanced non-small cell lung cancer: a phase III randomised trial of 3 versus 6 courses of mitomycin C, vinblastine, cisplatin. Proc Am Soc Clin Oncol 1998, 17:457a. This unique and interesting study found no difference in terms of survival or response between three and six cycles of MVP chemotherapy.

    Google Scholar 

  34. Shepherd FA, Dancey J, Ramlau R, et al.: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer patients previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18:2095–2103.

    PubMed  CAS  Google Scholar 

  35. Fossella FV, De Vore R, Kerr RN, et al.: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000, 18:2354–2362.

    PubMed  CAS  Google Scholar 

  36. Crino L, Mosconi M, Scagliotti G, et al.: Gemcitabine as second-line treatment for advanced non-small cell lung cancer: a phase II trial. J Clin Oncol 1999, 17:2081.

    PubMed  CAS  Google Scholar 

  37. Hainsworth JD, Burris HA, Litchy S, et al.: Gemcitabine and vinorelbine in the second line treatment of non small cell lung carcinoma patients: a Minnie Pearl Cancer Research Network phase II trial. Cancer 2000, 88:1353–1358.

    Article  PubMed  CAS  Google Scholar 

  38. Kraut MJ, Rusch VW, Crowley JJ, et al.: Induction chemoradiation plus surgical resection is a feasible and highly effective treatment for Pancoast tumors: initial results of SWOG 9416 (Intergroup 0160) trial. Proc Am Soc Clin Oncol 2000, 19:487a.

    Google Scholar 

  39. Kelly K, Bunn PA: Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer? Lung Cancer 1998, 20:85–91.

    Article  PubMed  CAS  Google Scholar 

  40. Ettinghausen SE, Burt ME: Prospective evaluation of unilateral adrenal masses in patients with operable non-small cell lung cancer. J Clin Oncol 1991, 9:1462–1466.

    PubMed  CAS  Google Scholar 

  41. Luketich JD, Martini N, Ginsberg RJ, et al.: Successful treatment of solitary extracranial metastases from non-small cell lung cancer. Ann Thorac Surg 1995, 60:1609–1611.

    Article  PubMed  CAS  Google Scholar 

  42. Belani CP, Natale RB, Lee JS, et al.: Randomized phase III trial comparing cisplatin/etoposide versus carbo-platin/ paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1998, 17:455a.

    Google Scholar 

  43. Sandler AB, Neumanitis J, Denham C, et al.: Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 2000, 18:122–130.

    PubMed  CAS  Google Scholar 

  44. Bonomi P, Kim K, Fairclough D, et al.: Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000, 18:623–631.

    PubMed  CAS  Google Scholar 

  45. Santomaggio C, Tucci E, Rinaldini M, et al.: Carboplatin and vinorelbine in the treatment of advanced non-small cell lung cancer. Am J Clin Oncol 1998, 21:6771.

    Article  Google Scholar 

  46. Le Chevalier T, Berille J, Zalcberg JR, et al.: Overview of docetaxel (taxotere)/cisplatin combination in non-small cell lung cancer. Semin Oncol 1999, 26(suppl):13–18.

    PubMed  Google Scholar 

  47. Masuda N, Fukuoka M, Negoro S: Randomized trial comparing cisplatin and irinotecan versus CDDP and vindesine vs. CPT-11 alone in advanced non-small cell lung cancer: a multicenter Phase III study. Proc Am Soc Clin Oncol 1999, 18:459a.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Greenebaum Cancer Center, University of Maryland, 22 S. Greene Street, 21201-1595, Baltimore, MD, USA

    Martin J. Edelman MD & Shyam L. Khanwani MD

Authors
  1. Martin J. Edelman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shyam L. Khanwani MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Edelman, M.J., Khanwani, S.L. Advanced non-small cell lung cancer. Curr. Treat. Options in Oncol. 2, 51–62 (2001). https://doi.org/10.1007/s11864-001-0016-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-001-0016-6

Keywords

Search

Navigation